Pulmozyme DNase data

GNE presented data at the North American Cystic Fibrosis Conference in Orlando showing that Pulmozyme is effective in treating CF patients with severe obstructive lung disease (forced vital capacity < 40 percent). These patients were sicker than the patients tested in GNE's original Phase III study, in which entry was limited to patients whose FVC was > 40 percent of predicted.

A total of 320 patients were recruited in the U.K. and U.S. and treated for three months. Administration of Pulmozyme significantly improved forced expiratory volume in 1 second (FEV1) (7.3 per cent) and FVC (5.1 percent) compared to placebo. ...